EQRX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 lapkr. 2023 @ 23:00):

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States...

Stats
Šios dienos apimtis	11.93M
Vidutinė apimtis	2.95M
Rinkos kapitalizacija	1.14B
EPS	$-0.180 ( 2023-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.25
ATR14	$0.0660 (2.82%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-09	Casdin Eli	Sell	5 488 164	Common Stock
2023-11-09	Casdin Eli	Sell	8 110 001	Warrants to purchase Class A Common Stock (right to buy)
2023-11-09	Casdin Eli	Sell	755 766	Earn-out Shares
2023-11-09	Casdin Eli	Sell	101 010	Stock Option (Right to Buy)
2023-11-09	Nallicheri Melanie	Buy	626 999	Common Stock

INSIDER POWER
-96.19
Last 94 transactions
Buy: 76 186 838 \| Sell: 93 441 879

Tūris Koreliacija

Ilgas: 0.04 (neutral)

Trumpas: -0.25 (neutral)

Signal:(55.606) Neutral

EQRx, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
BSRR	0.931
MPAA	0.931
CLGN	0.931
ENG	0.929
CNSP	0.929
CPTN	0.927
VBTX	0.926
MYFW	0.926
UBFO	0.925
BPYPN	0.924

10 Labiausiai neigiamai susiję koreliacijos
RMBS	-0.899
LYTS	-0.898
DSPG	-0.897
CCRC	-0.895
KE	-0.894
JMPNZ	-0.893
ISDX	-0.893
PPYAU	-0.892
IEUS	-0.891
HEWG	-0.89

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

EQRx, Inc. Koreliacija - Valiuta/Žaliavos

0.03
( neutral )

-0.06
( neutral )

0.69
( moderate )

0.42
( neutral )

-0.79
( moderate negative )

-0.42
( neutral )

EQRx, Inc. Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$0.430

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$0.430

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.205

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.513

Financial Reports:

No articles found.

EQRx, Inc.

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.